Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study

Circulation

Volumn 99, Issue 1, 1999, Pages 73-80

  Greinacher, A ^a   Volpel H ^b   Janssens, U ^c   Hach Wunderle, V ^d   Kemkes Matthes, B ^e   Eichler, P ^a   Mueller Velten, H G ^f   Potzsch B ^g  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Behringwerke AG   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d William Harvey Clinic   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f Centeon Pharma GmbH   (Germany)

^g KERCKHOFF HEART CENTER   (Germany)

Author keywords

Anticoagulants; Heparin; Immunology; Platelets; Thrombosis; Trials

Indexed keywords

LEPIRUDIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE ACTIVATION; THROMBOCYTE LIFESPAN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

EID: 0345369740     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.1.73     Document Type: Article

References (36)

1. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1-7.
2. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
3. Amiral J, Wolf M, Fischer AM, Boyer-Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol. 1996; 92:954-959.
4. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost. 1995;21:106-116.
5. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost. 1992;67:545-549.
6. Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95-96.
7. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
8. Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
9. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
10. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72:925-930.
11. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 1989;73:235-240.
12. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316: 581-589.
13. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
14. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org10172). Thromb Haemost. 1993; 70:554-561.
15. Demers C, Ginsberg JS, Brill-Edwards P, Panju A, Warkentin TE, Anderson DR, Turner C, Kelton JG. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood. 1991;78:2194-2197.
16. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost. 1995;73: 21-28.
17. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4-heparin enzyme linked immunosorbent assay. Transfusion. 1994;34:381-385.
18. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost. 1997;23:197-202.
19. Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev. 1992;10:211-232.
20. Weitz JI, Huboda M, Massel D, Marganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
21. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83:1535-1541.
22. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984;100:535-540.
23. AbuRahma AF, Boland JP, Witsberger T. Diagnostic and therapeutic strategies of white clot syndrome. Am J Surg. 1991;162:175-179.
24. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of the whole blood ecarin clotting time. Thromb Haemost. 1997;77:920-925.
25. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66:734-736.
26. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley & Sons; 1980.
27. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, Calif: Lifetime Learning Publications; 1982.
28. Ulm K, Schmoor C, Sauerbrei W, Kemmler G, Aydemir Ü, Müller B, Schumacher M. Strategies for evaluation of a therapeutic trial with survival time as endpoint (in German). Biometrie Informatik Medizin. 1989;20:171-205.
29. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, During W, Harmjanz D, Kötter V, Kalhammer E, Simon H, Horacek T. Safety observation from the pilot phase of the randomized R-Hirudin for Improvement of Thrombolysis (HIT III) study: a study of the Arbeitsgemeinschaft Leitender kardiologischer Krankenhausärzte (ALKK). Circulation. 1994;90:1638-1642.
30. Parent F, Bridey F, Dreyfus M, Musset D, Grimon G, Duroux P, Meyer D, Simonneau G. Treatment of severe thromboembolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost. 1993; 70:386-388.
31. Vanholder R, Camez A, Veys N, Soria J, Mirshahi MC, Soria C, Ringoir S. Recombinant hirudin: a specific thrombin-inhibiting anticoagulant for hemodialysis. Kidney Int. 1994;45:1754-1759.
32. Rupprecht HJ, Terres W, Özbek C, Luz M, Jessel A, Hfner G, vom Dahl J, Kromer EP, Prellwitz W, Meyer J. Recombinant hirudin (HBW 023) prevents troponin release after coronary angioplasty in patients with unstable angina. J Am Coll Cardiol. 1995;26:1637-1642.
33. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med. 1995;332:1374-1376. Editorial.
34. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
35. Antman EM, for the TIMI 9A investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 1994;90: 1624-1630.
36. Greinacher A, Philippen KH, Kemkes-Matthes B, Möckel M, Mueller-Eckhardt C. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis. Nephrol Dial Transplant. 1993;8:1176-1177.